NASDAQ:LYRA Lyra Therapeutics Q4 2023 Earnings Report $6.70 -0.19 (-2.76%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$6.56 -0.14 (-2.01%) As of 08/8/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Lyra Therapeutics EPS ResultsActual EPS-$11.00Consensus EPS -$16.50Beat/MissBeat by +$5.50One Year Ago EPSN/ALyra Therapeutics Revenue ResultsActual Revenue$0.15 millionExpected Revenue$0.52 millionBeat/MissMissed by -$370.00 thousandYoY Revenue GrowthN/ALyra Therapeutics Announcement DetailsQuarterQ4 2023Date3/21/2024TimeN/AConference Call DateThursday, March 21, 2024Conference Call Time4:00PM ETUpcoming EarningsLyra Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled on Friday, August 15, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Lyra Therapeutics Earnings HeadlinesLyra Therapeutics (NASDAQ:LYRA) Shares Up 3.8% - What's Next?August 5, 2025 | americanbankingnews.comLyra Therapeutics Board Chair Waksal Steps DownAugust 2, 2025 | marketwatch.comREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!). | Weiss Ratings (Ad)Lyra Therapeutics Announces Leadership Changes in August 2025August 2, 2025 | msn.comLyra Therapeutics, Inc. Announces Definitive Agreement for Registered Direct Offering and Private Placement of Common Stock and Warrants - NasdaqJune 29, 2025 | nasdaq.comLyra Therapeutics to raise up to $15M via registered direct offering and concurrent private placement, stock falls 22%June 27, 2025 | msn.comSee More Lyra Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lyra Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lyra Therapeutics and other key companies, straight to your email. Email Address About Lyra TherapeuticsLyra Therapeutics (NASDAQ:LYRA), a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.View Lyra Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Airbnb Beats Earnings, But the Growth Story Is Losing AltitudeDutch Bros Just Flipped the Script With a Massive Earnings BeatIs Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?Constellation Energy’s Earnings Beat Signals a New EraRealty Income Rallies Post-Earnings Miss—Here’s What Drove ItDon't Mix the Signal for Noise in Super Micro Computer's EarningsWhy Monolithic Power's Earnings and Guidance Ignited a Rally Upcoming Earnings SEA (8/12/2025)Cisco Systems (8/13/2025)Alibaba Group (8/13/2025)NetEase (8/14/2025)Applied Materials (8/14/2025)Petroleo Brasileiro S.A.- Petrobras (8/14/2025)NU (8/14/2025)Deere & Company (8/14/2025)Palo Alto Networks (8/18/2025)Medtronic (8/19/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
